IPCA Laboratories

IPCA Laboratories Total Assets

The Total Assets of IPCA Laboratories (IPCALAB.NS) as of Nov 7, 2026 is 123.70 B INR. In the previous year, Total Assets was 117.61 B INR — a change of 5.18% (higher).

Total Assets

123.70 BINR

YoY

5.18%

Last updated:

Total Assets of IPCA Laboratories is 2026 123.70 B INR. Total Assets of IPCA Laboratories was 2025 117.61 B INR. It decreases by 5.18% higher compared to the previous year.

The IPCA Laboratories Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2019
45.51 B INR
Jan 1, 2020
52.60 B INR
Jan 1, 2021
60.68 B INR
Jan 1, 2022
76.24 B INR
Jan 1, 2023
86.26 B INR
Jan 1, 2024
111.01 B INR
Jan 1, 2025
117.61 B INR
Jan 1, 2026
123.70 B INR
The IPCA Laboratories Total Assets history
YEARTotal AssetsYoY
123.70 BINR+5.18%
117.61 BINR+5.94%
111.01 BINR+28.69%
86.26 BINR+13.16%
76.24 BINR+25.63%
60.68 BINR+15.37%
52.60 BINR+15.58%
45.51 BINR+10.53%
41.17 BINR+3.99%
39.60 BINR+1.74%
38.92 BINR+2.08%
38.12 BINR+18.74%
32.11 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Total Assets of IPCA Laboratories is 123.70 B INR in 2026.

Total Assets of IPCA Laboratories changed from 117.61 B INR to 123.70 B INR, representing a 5.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's IPCA Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IPCA Laboratories

All Key Metrics — IPCA Laboratories